Ramón
García Sanz
![Foto de Ramón](/img/uploaded/1ac626506eb5a6916a2a5159808e81e0.jpg)
![Foto de Universidad de Salamanca](/img/noimage_org.png)
Universidad de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Salamanca (70)
2023
-
Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study
Blood Cancer Journal
-
Characterization of the first HLA-DQA1 allele with Aspartic Acid in the transmembrane domain, HLA-DQA1*05:71
HLA, Vol. 102, Núm. 3, pp. 381-383
-
Detection and characterization of the novel HLA-DPA1*02:66:02N allele, with a premature stop codon in exon 2
Human Immunology, Vol. 84, Núm. 4, pp. 296-300
-
Identification of the novel HLA-DQA1*01:04:07 allele with a synonymous substitution and an intronic insertion
HLA, Vol. 101, Núm. 5, pp. 559-561
-
Identification of two novel HLA-DQB1*03:01:01 intronic variants: HLA-DQB1*03:01:01:47 and -DQB1*03:01:01:48
HLA, Vol. 101, Núm. 5, pp. 562-564
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
The novel HLA-DQB1*03:02:01:14 allele was possibly generated by a recombination event
HLA, Vol. 102, Núm. 2, pp. 258-260
-
Transitions in intronic regions result in two novel HLA-DQB1 alleles: –DQB1*05:02:01:13 and -DQB1*05:02:01:14
HLA, Vol. 102, Núm. 2, pp. 260-262
2022
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma
Science Advances, Vol. 8, Núm. 3
-
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
Experimental Hematology and Oncology, Vol. 11, Núm. 1
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
2020
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Blood Advances, Vol. 4, Núm. 23, pp. 6023-6033
-
Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression
Cellular Oncology, Vol. 43, Núm. 4, pp. 743-750
2018
-
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Blood cancer journal, Vol. 8, Núm. 12, pp. 117
2017
-
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106
-
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Leukemia, Vol. 31, Núm. 10, pp. 2094-2103
2016
-
Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders
Haemophilia, Vol. 22, Núm. 4, pp. 590-597